Edition:
United Kingdom

Natco Pharma Ltd (NATP.NS)

NATP.NS on National Stock Exchange of India

790.20INR
11:27am BST
Change (% chg)

Rs36.15 (+4.79%)
Prev Close
Rs754.05
Open
Rs754.00
Day's High
Rs798.80
Day's Low
Rs753.20
Volume
303,465
Avg. Vol
311,325
52-wk High
Rs1,090.00
52-wk Low
Rs671.10

Chart for

About

Natco Pharma Limited is a pharmaceutical company. The Company is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The Company's segments include active pharmaceuticals ingredient, finished dosage formulations, job works, pharmacy and others. The... (more)

Overall

Beta: 0.37
Market Cap(Mil.): Rs173,105.09
Shares Outstanding(Mil.): 174.31
Dividend: 1.25
Yield (%): 0.73

Financials

  NATP.NS Industry Sector
P/E (TTM): 32.37 30.95 32.75
EPS (TTM): 30.68 -- --
ROI: -- 14.84 14.38
ROE: -- 16.34 16.07

BRIEF-Natco Pharma Files ANDA to U.S. FDA For Sofosbuvir Tablets

* SAYS FILED AN ABBREVIATED NEW DRUG APPLICATION FOR SOFOSBUVIR TABLETS, 400MG, WITH U.S.‍​ FDA

01 Mar 2018

BRIEF-Gilead: Natco And Teva Requested FDA Permission To Make Generic Version Of Sovaldi - SEC Filing

* GILEAD SCIENCES INC SAYS IN FEBRUARY 2018, CO RECEIVED NOTICES FROM NATCO PHARMA LIMITED AND TEVA PHARMA - SEC FILING

27 Feb 2018

BRIEF-Natco Pharma Says Co's Mekaguda Facility Undergoing Routine U.S. FDA Inspection

* NATCO PHARMA CLARIFIES ON NEWS ITEM ON US FDA INSPECTION AT CO'S MEKAGUDA FACILITY IN TELANGANA

14 Feb 2018

BRIEF-India's Natco Pharma Dec-Qtr Consol Profit Rises

* DEC QUARTER CONSOL NET PROFIT 2.18 BILLION RUPEES VERSUS PROFIT 1.95 BILLION RUPEES YEAR AGO

06 Feb 2018

BRIEF-Natco Pharma Launches Tafnat, Tenofovir Alafenamide Tablets In India

* SAYS NATCO LAUNCHES TAFNAT, TENOFOVIR ALAFENAMIDE TABLETS, FOR TREATMENT OF CHRONIC HEPATITIS B, IN INDIA Source text for Eikon: Further company coverage:

18 Dec 2017

BRIEF-Natco Pharma Approved Allocation Of 10 Mln Shares At 915 Rupees/Share Upon Closure Of QIP

* NATCO PHARMA - APPROVED ALLOCATION OF 10 MILLION SHARES AT ISSUE PRICE OF 915 RUPEES PER SHARE UPON CLOSURE OF QIP Source text: http://bit.ly/2zbT0ZA Further company coverage:

14 Dec 2017

BRIEF-Natco Pharma Approves QIP Floor Price Of 937.63 Rupees/Shr

* SAYS APPROVED QIP FLOOR PRICE OF 937.63 RUPEES PER SHARE Source text: http://bit.ly/2AJA9El Further company coverage:

11 Dec 2017

Earnings vs. Estimates